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Abstract
Innovation in the medical device industry is crucial to continuously improve the health
and wellbeing of society. The U.S. Food and Drug Administration (FDA) is responsible for
ensuring the safety and effectiveness of medical devices on the market while balancing the need
for continuous innovation. One way the FDA has tried to support innovation is through the
development of the 510(k) pathway, which does not require clinical testing as the safety of the
device is determined based on a predicate device. Many companies choose to develop products
that can obtain approval through the 510(k) pathway. While the 510(k) pathway is shorter, it
does not allow for the type of rapid innovation and approval needed during a public health
emergency. The FDA has an alternate path, the Emergency Use Authorization (EUA), that
authorizes the use of certain devices during pandemics such as COVID-19.
The goal of this thesis was to identify the ways in which the COVID-19 EUA encouraged
innovation in the ventilator industry. The EUA provides an opportunity for new devices,
technologies, and players to enter the industry that would otherwise face regulatory barriers. This
study was completed using publicly available data to identify historical patterns in the ventilator
industry, changes in the industry from the 510(k) to the EUA, and innovation in ventilator
development. The analysis showed that there were new entrants to the ventilator market and
companies took multiple approaches to innovative solutions, from manufacturing to product
design. Based on my findings, I conclude with a number of policy recommendations.
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Introduction
Innovation is vital not only for the economy but for society as well. Problems and needs
of society are constantly changing, and the continuous nature of innovation allows needs to
remain fulfilled. This need for constant innovation is prominent in the medical device industry,
yet the medical device industry is one where innovation has been slow (Bergsland, Elle, & Fosse,
2014). The Food and Drug Administration (FDA) has tried to combat barriers to innovation by
establishing multiple device approval pathways.
The FDA implemented the Medical Device Amendments Act of 1976 to ensure the safety
and effectiveness of medical devices. This act defined the premarket approval (PMA) and
premarket notification (PMN) 510(k) pathways that are still in use today. The PMA is utilized
for high-risk devices and is expected to have a 180-day review process. The 510(k) is a quicker
process, with a projected timeline of 90 days, and is used for low to medium risk devices. The
510(k)-process had two public health goals: to ensure that medical devices are safe and effective
while facilitating innovation. Soon after the 510(k) was established, it became clear that it was
not meeting its goal of facilitating innovation while maintain product safety. The medical device
industry had raised concerns about the 510(k) process being unpredictable and not transparent,
which suppressed innovation and led to more devices being sent overseas rather than in the
United States (US) (FDA 510(k) Report, 2010). In addition to inhibiting innovation, safety
requirements were still not being met, and studies found that devices approved through the
510(k) from 2005 to 2009 were involved in 71% of device recalls that resulted in severe health
impacts or death (Zuckerman, Brown, & Nissen, 2011). There is a delicate balance between
safety and innovation that has yet to be found.
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The 510(k) is one of the shorter FDA processes, but the timeline of 90 days and the
administrative burden of submission does not allow it to be useful in times of a public health
crisis, such as coronavirus. The Emergency Use Authorization (EUA) of Medical Products was
established in 2008. The EUA is meant to promote the development and availability of specific
medical devices and products during national emergencies (FDA EUA, 2017). Medical devices
that obtain EUA authorizations are only valid for when the public health emergency is a concern.
The timeline for authorization is not explicitly stated, but it is significantly shorter than the
510(k) approval process. Both the 510(k) and EUA pathways have goals of promoting medical
device innovation.
COVID-19 is a respiratory virus that was deemed a public health emergency in January
2020. Patients with severe symptoms often require the support of a ventilator. An EUA was
enacted during COVID-19 for certain medical devices, including ventilators. Hospitals typically
have a limited supply of full-service ventilators that are expensive and complex to use. In the
event of a respiratory virus pandemic, ventilator shortages are a significant concern (Kulish,
Kliff, & Silver-Greenberg, 2020). In the case of COVID-19, the EUA allowed for alternative
uses of existing medical devices and temporary authorization of new ventilator designs.
This thesis will examine how a shift in regulatory procedure and expectations can impact
innovative solutions in the medical device industry, specifically related to ventilators considering
the COVID-19 pandemic. The first part of my thesis will be a literature review on barriers to
innovation in the medical device industry and early innovative responses to COVID-19. I then
discuss my research question and outline the methodology for data collection and analysis. I then
present the findings from my research and discuss the nature of innovation in EUA authorized
ventilators. I conclude with implications for policy and future research.
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Background
COVID-19
In late December 2019, Wuhan China reported a cluster of pneumonia cases. These cases
were identified to be severe acute respiratory syndrome (SARS) - 2019 novel coronavirus. By
January 30, the World Health Organization (WHO) declared a public health emergency of
international concern (WHO, 2020). Since then, the exponential global spread of COVID-19 has
led governments across the world to take various precautions to attempt to slow the spread and
treat this disease.
COVID-19 is a severe respiratory disease that has severe short and long-term impacts on
the breathing capabilities of persons who contract the disease. Patients who experience severe
symptoms often need a ventilator’s assistance to ensure proper exchange of oxygen and carbon
dioxide into and out of the body. Ventilators have been in high demand since the beginning of
the pandemic, and many countries have been aware of the shortage of ventilators (Kliff,
Satariano, Silver-Greenberg, & Kulish, 2020). One study has estimated the projected need for
invasive and noninvasive ventilators by studying recent COVID-19 hospitalizations (Wells, et
al., 2020). Table 1 shows there is a 45,341 invasive ventilator shortage and a 77,289 noninvasive
ventilator shortage in the United States (U.S.) as of October 2020.
Table 1: Projected Need for Ventilators in the USA at COVID-19 Peak (Wells, et al., 2020)

115,001
98,015
28,355

Noninvasive Ventilator
Count
89,788
22,976
10,477

69,660

12,499

45,341

77,289

Invasive Ventilator Count
Total Estimated Need
Current Inventory
Non COVID-19 Use
Available for COVID-19
Use
Additional Estimated Need
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Current intensive care ventilators can cost as much as $50,000 and are complex machines
with thousands of components that require highly trained professionals to operate them. As of
March 18, 2020, American and international ventilator manufacturers said they would not be
able to meet the soaring demand for ventilators anytime soon (Kliff, Satariano, Silver-Greenberg,
& Kulish, 2020). Additionally, less than a dozen U.S. companies make ventilators. Foreign
companies make about half the intensive care ventilators used in the U.S., and COVID-19 has
caused a massive delay in shipping these ventilators to customers in the United States and
elsewhere (Kliff, Satariano, Silver-Greenberg, & Kulish, 2020). One measure that the FDA has
taken to combat the shortage of ventilators is the Emergency Use Authorization (EUA) for
COVID-19 medical devices, which will be explained more in the following section.

FDA Pathways
There are multiple pathways to approval for a medical device based on its classification.
The device classification defines the risk associated with the device and determines the level of
inspection and materials needed for the FDA review (FDA Pathway to Approval, 2018).
Class I: Low-risk devices – only require general control. Most are exempt from
premarket submissions.
Class II: Moderate risk – require general and specific controls. The typical pathway is the
Premarket Notification (PMN) 510(k).
Class III: Life-supporting or life-sustaining devices – Typically require Premarket
Approval (PMA).
Ventilators are considered a class II device, so they must go through the 510(k) process.
Under the 510(k) pathway, companies identify substantial equivalence to a predicate device.
Substantial equivalence can be claimed when the new device has similar indications for use and
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technological characteristics as a prior approved device. Companies do not need to complete
clinical trials for the 510(k), as substantial equivalence is meant to prove that the new device will
be at least as safe and effective as the predicate device (FDA Pathway to Approval, 2018). The
510(k) pathway is preferred by companies as there are fewer filing requirements, and the process
is generally quicker and less expensive than the PMA pathway.
The EUA pathway is enacted by the FDA when a public health emergency can
significantly affect the health and security of the United States. As stated by the FDA (FDA
EUA COVID-19, 2020),
“Section 564 of the Federal Food, Drug, and Cosmetic Act the FDA may allow
unapproved medical products or unapproved uses of approved medical products to be
used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or
conditions when there are no adequate, approved, and available alternatives”
Devices approved through the EUA can only be used while the EUA is in order. Once the
public health emergency is resolved, the products must be taken off the market or returned to
their original intended use. COVID-19 EUA’s have been enacted in the following categories:
blood purification devices, hemodialysis devices, In Vitro diagnostics, decontamination systems
for personal protective equipment (PPE), infusion pumps, PPE, remote or wearable patient
monitoring devices, respiratory assist devices, ventilators, ventilator accessories, and other
medical devices. The EUA contains fewer barriers than other FDA pathways, as its main goal is
to get essential devices out as quickly as possible.
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Literature Review
This literature review aimed to identify and understand barriers to innovation in the
medical device industry and see what was already known about innovative responses during
COVID-19. The first part of the review analyzes the most common barriers to innovation and
how these barriers affect the amount and type of innovation in the medical device industry. The
second part of the literature review analyzes innovative responses to COVID-19 to identify what
is already known and what needs to be studied further.

Barriers to Medical Device Innovation
Innovation in the medical device industry is crucial to both improving existing solutions
and creating novel solutions. As shown in Table 2, the most common impacts on medical device
innovation mentioned in the literature were regulatory processes, firm size, academia and
industry, and pricing.
Table 2: Barriers to innovation identified in the literature

Author
(Bayon, et
al., 2016)
(Bergsland,
Elle, &
Fosse, 2014)
(Goodman &
Gelijns,
1996)
(Kahn, 1991)
(Krucoff,
Brindis,
Hodgson,
Mack, &
Holmes,
2012)
(Roberts,
1988)

Conservative
Regulatory
Medical
Firm Size
Process
Patterns

Academia
and
Industry

Patents

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

Pricing

X

X

X

X
11

Regulatory Processes
The most common barrier to innovation mentioned in the medical device industry is the
regulatory process. The FDA has regulatory pathways in place to help ensure the safety and
effectiveness of devices that enter the market. An intensive process is beneficial for determining
the safety of devices, but there are aspects of the process that have negatively impacted
innovation in the medical device industry.
The biggest issue of the FDA regulatory process is its unpredictability, which can affect
the length and cost of the approval process. An unpredictable process leaves firms hesitant to
introduce new products as they do not know how long it will take to get a return on their
investment (Krucoff, Brindis, Hodgson, Mack, & Holmes, 2012). A slow and costly process also
makes it difficult for small or new firms to enter the industry. Small firms do not have financial
stability, and the lag time between creating a device and getting it onto the market can be
detrimental for the business (Roberts, 1988). With an unpredictable process, firms of all sizes are
hesitant to create new products for approval.
Additionally, as seen in the table above, the medical device industry has conservative
medical patterns. Approval time for new and innovative devices is significantly longer than if
substantial equivalence to a predicate can be claimed, allowing the use of the 510(k) pathway.
Bergsland et al. (2014) perceive the 510(k) pathway as a disincentive to be the first firm to create
a new product. Companies choose to pursue “me too” products more often as the process is less
burdensome. A novel claim is not worth the regulatory risk for many firms (Bayon, et al., 2016).
This conservative medical pattern is not only seen in the regulatory pathway but in places of care
as well. Introducing new technology to hospitals is complicated, making it difficult for new
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technologies to become the standard of care (Bergsland, Elle, & Fosse, 2014). Conservative
patterns will be discussed further in the pricing section below.
Barriers to Innovation based on Firm Size
As mentioned in the regulatory processes section, some barriers pose a greater risk to
firms based on their size. Smaller companies are more likely to pursue early-stage innovation
and produce novel products. Small firms are typically started to fill a need in the market that has
not been met yet (Roberts, 1988). One example of this is solutions for orphan diseases. Orphan
diseases are rare diseases that affect less than 200,000 people in the U.S., and most devices made
for this group are created by small firms, as large firms generally want to focus on a larger
market (Kahn, 1991). Early innovation is typically done on a smaller scale, and small firms often
create disruptive technology that becomes a target for large firms. Bayon et al. (2016) mention
that there has been a decline in the rate of innovation at the industry level. When larger
companies do innovate, they typically focus on the end of the development process, such as
improving existing devices rather than producing new ones.
Another source of innovation for medical devices are devices created at universities.
Bergsland et al. (2014) mention that new devices often stem from academia, which has created
conflicts in partnerships between universities and firms. Academic projects are typically
completed with the goal of publication, but this can interfere with intellectual property rights for
a firm. High approval costs and complicated processes also make it difficult for universities to
pursue approval for novel devices on their own (Goodman & Gelijns, 1996). Since small firms
and universities are often the ones creating novel devices, a costly and unpredictable regulatory
process prohibits innovative devices from entering the market.
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Pricing
An additional barrier mentioned by four of the studies are concerns around product
reimbursement and insurance. Market sizes for medical devices are relatively small compared to
other markets such as personal electronics. Smaller market sizes lead to higher-priced products,
this way, a company can still to produce a profit (Bergsland, Elle, & Fosse, 2014). Many medical
devices are too costly for an average person to pay for on their own. This is where pricing
impacts innovation.
First, insurance coverage can be unpredictable. Insurance often will not cover a device
until its effectiveness has been proven. This is difficult for firms as hospitals are hesitant to
introduce new technology unless significant cost-effectiveness is shown or the device has a huge
value for society (Kahn, 1991). Companies tend to design devices that are reimbursable within
existing insurance codes, but this can put a cap on the amount of innovation involved.
Second, there is no promise that insurance will cover a device, which discourages the
introduction of new technology by companies. Minimal to no insurance coverage would decrease
profitability for the firm as healthcare providers would hesitate to recommend a device that
patients need to pay for out of pocket (Bayon, et al., 2016). Additionally, reimbursement
decisions are ambiguous and typically are not decided until after a device is approved (Krucoff,
Brindis, Hodgson, Mack, & Holmes, 2012). Overall, the potential for insurance coverage and
reimbursements impacts the level of innovation involved with updating a current device or
creating a new medical device.
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Patents
The last barrier to innovation mentioned in Table 2 is patenting. Patents are both an
incentive and a barrier to innovation in the medical device industry. The incentive with patents is
clear as a company will obtain exclusive rights to their product and can increase prices without
competition. The barrier occurs when large companies cover their products with general patents.
This makes it more difficult for smaller companies to enter the market and discourages
innovation in that field (Bergsland, Elle, & Fosse, 2014). Kahn (1991) noted a difference
between patents in the pharmaceutical industry versus the medical device industry. He stated that
pharmaceutical patents are less of a barrier as the basic principle of a drug is not patentable but
rather the drug itself. An example he provides is that the use of antihistamines to treat allergies is
not patentable, but the specific molecule configuration is. In contrast, patents in the medical
device industry tend to focus on the principle of the product, not the particular technology or
device (Kahn, 1991). Overall, the patenting approach in the medical device industry discourages
innovation.

Innovation during COVID-19
The first part of this literature review shows that there are multiple factors that inhibit
innovation in the medical device industry. The COVID-19 pandemic has had a unique effect on
the ventilator industry. Ventilators are typically large, complex, expensive devices that are used
in intensive care units. The impact of COVID-19 on respiratory systems has created a dire need
for increased ventilator inventory worldwide. The only feasible way to fulfill this order is to
remove or reduce the barriers to innovation mentioned above. Due to the novel nature of
COVID-19, there are only a few published articles about innovation during COVID-19. The
articles that are published only have a few references and study a limited number of solutions.
15

These articles can be seen in Table 3. The literature analyzes the effect of the pandemic on
technology, innovation, and lessons learned. Overall, the pandemic sparked various innovative
responses and provided learning opportunities for the medical device industry.
Table 3: Summary of articles on innovation during COVID-19

Author
(Brem, 2020)
(Chesbrough, 2020)
(Farrugia & Plutowski,
2020)
(Harris, Bhatti, Buckley, &
Sharma, 2020)
(Lee & Trimi, 2020)

(Morton, 2020)

(Mulligan, 2020)

(Von Krogh, Kucukkeles, &
Ben-Menahem, 2020)
(Woolliscroft, 2020)

Purpose
Analyze the effects of the
worldwide pandemic on
technology.
Discuss managing innovation
and lessons learned.
Discuss innovative lessons
from COVID-19.
Review of frugal innovation
measures in response to
COVID-19.
Presents convergence
innovation as a catalyst for
managing COVID-19.
Describe incentives for
innovation normally versus in
a pandemic.
Quantify economic sacrifices
and how to reduce the
economic burden.
Present an altered approach to
innovation and lessons
learned.
Analyze exemplary
innovations and how they
will last past COVID-19.

Conclusion
The pandemic forced the
widespread adoption of
existing technologies.
Openness speeds up the
innovation process.
Emergence of enhanced
digital care options.
Necessity drives innovation
and resourcefulness shines in
times of crisis.
Many solutions would not be
possible without convergence
of different ideas.
COVID-19 provided
incentives to create cheaper
ventilators.
Medical innovation can
reduce the intensity of
COVID-19, reducing the
ultimate economic impact.
Innovation based on
repurposing will likely be
promising.
Multiple innovations will be
promising for use past
COVID-19.

The first thing the COVID-19 literature revealed was the range of innovation types
between the articles. Innovation is a term that can be applied in different ways based on the topic
of interest. Differences in types lie in what technologies, ideas, and resources are used and how
they are applied to a solution. The innovation types and descriptions referenced in the articles
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reviewed on COVID-19 innovation are stated in Table 4. Even though there may be different
aspects of each type, they all promote a new or improved product as a result.
This research paper’s definition of innovation is a change that occurred whether it is due
to the intended use, product design, or product development. The change in the product must
have a degree of novelty and usefulness to the ventilator industry.
Table 4: Innovation types and descriptions from literature review articles

Author

Type

(Chesbrough, 2020)

Open

(Harris, Bhatti,
Buckley, & Sharma,
2020)

Frugal

(Lee & Trimi, 2020)

Convergence

(Von Krogh,
Kucukkeles, & BenMenahem, 2020)

Rapid

“innovation centered on repurposing of readily
available ideas, knowledge, and technologies”

General

“technologies that have evolved as a result of the
pandemic, which may result in the development of
new and practical solutions to current and future
problems”

(Brem, 2020)

Description
“a distributed innovation process involving purposive
knowledge flows across organizational boundaries for
monetary or non-monetary reasons”
“doing more, with less, and being creative,
innovative, and resourceful in the face of institutional
voids and resource constraints”
“deployment of new ideas and/or technologies in
fundamentally different ways to create new or
additional value for continued success of the
organization and its stakeholders”

Most of the articles found around COVID-19 innovation discussed what lessons have
been learned. Table 5 categorizes the lessons learned from each article. The most common ones
include various efforts in collaboration and technology use. These will be discussed in more
detail below.
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Table 5: Lessons learned in innovation from COVID-19

Author
(Brem, 2020)
(Chesbrough,
2020)
(Farrugia &
Plutowski, 2020)
(Harris, Bhatti,
Buckley, &
Sharma, 2020)
(Lee & Trimi,
2020)
(Von Krogh,
Kucukkeles, &
Ben-Menahem,
2020)

End
Users
X

Map
Resources
X
X
X

X

Use Emerging
Technology
X

Collaboration

Resourceful

X
X

X

X

X

X

X
X

X

X

X

X

X

X

Collaboration
Collaboration was identified as a lesson learned in innovation by all the articles reviewed.
This idea was mentioned in various ways, including general collaboration, government
collaboration, open communication, and mapping of resources and technology. Countless
COVID-19 solutions have stemmed from some sort of collaboration, whether it be crosssectorial, cross-disciplinary, international, or governmental. These collaborations have fostered
innovation as industries quickly shifted their goals to find solutions to one common problem
(Brem, 2020). Partnerships between seemingly unrelated industries have allowed for various
types of contributions; while one partner may be the device expert, another may provide the
financial capability, and another may have the manufacturing space and personnel to scale up
production rapidly. One example of this type of partnership is medical device companies
partnering with car manufacturers. The medical company has the expertise and regulatory
experience to produce a ventilator quickly. Still, their manufacturing spaces are typically smaller
scale as they do not need large amounts of their product made (Farrugia & Plutowski, 2020). The
pure number and scale of partnerships that have been created due to COVID-19 may provide
18

quicker relief for future pandemics as well. Companies have been able to build relationships that
they may not have built otherwise. This experience has shown the significant solutions that can
come to fruition when there is a common goal in mind. Another type of collaboration specifically
mentioned was government collaboration. The government has made some temporary
modifications to its policies to allow COVID-19 solutions to enter the market quickly. One
method the government uses to complete this is public-private partnerships. Additionally, there
have been some measures to increase flexibility in the regulatory processes for areas such as
clinical testing, medical devices, and the use of virtual care such as telehealth (Farrugia &
Plutowski, 2020).
Intentional communication is another skill that innovators utilized during COVID-19.
The end-users of many COVID-19 solutions are patients and physicians. Groups working on
various solutions emphasized the importance of incorporating the end-user into the design
process as soon as possible. Usability studies are a common practice used in product
development to gain a better understanding of how users will interact with their devices. This is
especially important when creating medical devices. Intuitive medical devices provide much less
of a safety risk than devices with many similar buttons and confusing alarm signals.
Incorporating physicians in the early stages of product design allows innovative groups to design
specifically for the end-user. Additionally, physicians may also be a great source of innovative
ideas (Chesbrough, 2020). Generally, no one understands the importance of a design better than
the end-users themselves, and it is the engineer’s job to build a device that fits their needs as
closely as possible. Communicating setbacks in design or production openly is another way to
expedite innovation (Von Krogh, Kucukkeles, & Ben-Menahem, 2020). If a firm or individual
has a problem with a specific design, part, or concept, there may be someone out there who has

19

already found a solution to this problem. In a time of crisis, there is not enough time for people
to sit and figure out problems independently. The most productive way to innovate rapidly is to
communicate with others and integrate suggested solutions.
The last section relating to collaboration is mapping resources and technology to build a
network of knowledge. Lee and Trimi (2020) state that collective intelligence is required to
achieve a common goal. An effective way to collect knowledge is to make an inventory of
existing resources. This can include capable facilities, databases, software, existing products,
talent, and expertise (Von Krogh, Kucukkeles, & Ben-Menahem, 2020). Everything that an
individual can think of that may be remotely helpful should be added to this web of knowledge.
Creating these large networks encourages collaboration in problem-solving as there are many
different avenues people take to develop products. There is no specific process that is better than
another, especially in a time of crisis (Farrugia & Plutowski, 2020). Collaboration between firms,
individuals, and universities, has undoubtedly had the largest impact on the sheer number of
innovative solutions developed in record time for COVID-19.
Technology Use and Resourcefulness
While collaboration has had an undeniable impact on the production of innovative
solutions, many of these solutions would not have been possible without the use of emerging
technology or innovative ways of using current technology. As mentioned in the earlier part of
the literature review, one barrier to innovation is the hesitancy of the medical device industry to
incorporate devices with drastic changes in technology. It is more difficult to file for regulatory
approval when substantial equivalence is not claimed and hospitals can be reluctant to use new
technology.

20

In light of this pandemic and the scarcity of previously available solutions, companies
have been pushed to incorporate technology that they may have been reluctant to adopt in the
past (Brem, 2020). Some of this technology includes the use of artificial intelligence (AI) and
machine learning. These options were quickly incorporated in the medical device industry to
help identify specific biological components that may help vaccine development or identify
between non-COVID-19 patients and COVID-19 patients based on their lung scans (Farrugia &
Plutowski, 2020). Another result of machine learning during COVID-19 was a machine that
could pair solutions with problems that have been shared in an open database (Von Krogh,
Kucukkeles, & Ben-Menahem, 2020). The use of emerging or new technology has shown to be
helpful in the production of innovative solutions, but resourcefulness has an impact as well.
Due to the supply chain issues caused by COVID-19, firms are thinking about product
development in a distinct way. They are trying to work with what they already have whether that
is using byproducts from their other products or using their existing facilities to their advantage.
This shift in innovation has been shown by the efforts of cosmetic companies and distilleries to
convert their sterile manufacturing systems to produce hand sanitizer (Von Krogh, Kucukkeles,
& Ben-Menahem, 2020). Resourcefulness is a more sustainable solution to innovation and
allows companies to work with materials they are already familiar with.
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Literature Review Summary
The major barriers to innovation cited in the literature were brought on by the
unpredictability and the cost of the regulatory process. COVID-19 has ignited a spark in
innovative medical devices and shown that there are feasible solutions to managing these
barriers. Some notable qualities of innovative efforts during COVID-19 have been the increase in
collaboration and the unique use of existing technology and resources. The pandemic provided a
common goal for people to work towards which increased the use of partnerships. Since
COVID-19 is a new disease, the literature on this topic is limited. The articles included in this
literature review were only able to analyze a few products and examples. From the information
gathered here, this thesis aims to build on the ideas established in these articles. This will be
done on a larger scale by studying 77 ventilators approved through the EUA.
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Research Question
The main purpose of this thesis is to determine the impact of the EUA on ventilator
innovation during COVID-19. The literature review suggests that there are challenges that exist
that impede medical device innovation, including challenges presented by the 510(k) pathway.
Times of crisis often result in innovative solutions and the EUA presents companies with a
unique opportunity to rapidly bring these solutions to the public. While the EUA is a temporary
authorization, it provides a framework with reduced regulatory barriers. To determine the impact
of the EUA on ventilator innovation, this thesis will conduct a qualitative assessment in an
attempt to answer the following research question:
What level and types of innovation did the COVID-19 EUA for ventilators generate?
This research question will be studied from various angles to provide a complete analysis.
First, 510(k) data will be analyzed to understand historical patterns of the ventilator industry.
Next, the EUA data will be analyzed to identify the types of organizations and ventilators that
obtained authorization. Finally, individual EUA ventilator designs and development processes
will be analyzed in depth to identify how and where innovation occurred.
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Methodology
Research Design
This paper will conduct a qualitative assessment to analyze public statements about the
nature of ventilator innovation generated by the COVID-19 EUA. I did this by using publicly
available data from the FDA website, Nexis Uni, company web pages, product brochures, and
Google. The use of available data and press releases was the most practical research design given
the novel nature of COVID-19 and limitations such as lack of access to EUA applications,
impracticality of interviewing with strained medical industry professionals due to COVID-19,
and the short timeline for thesis completion.

Data Collection
Initial data collection consisted of gathering information from the FDA. First, I
downloaded the releasable 510(k)s from 1976 to August 2020 from the “Downloadable 510(k)
Files” on the FDA website. Next, I collected EUA ventilator information from “Appendix B:
Authorized Ventilators, Ventilator Tubing Connectors, and Ventilator Accessories” from the
COVID-19 Emergency Use Authorizations for Medical Devices. Information was collected for
devices authorized between March 24th, 2020 and August 30th, 2020. EUA device information
from the FDA was limited, which led to additional data collection through Nexis Uni, company
web pages, product brochures, and Google.
Nexis Uni is an academic search engine that can search through various resources such as
the news. An advanced search was completed in Nexis using various combinations of the
following terms to obtain appropriate results: [company name], [device name], [EUA], [COVID19], and [ventilator]. News articles did not provide consistent information across companies and
products, so company web pages, product brochures, and Google were used to supplement the
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Nexis data. The following information was investigated from company web pages based on
available information: [EUA device], [press releases], and [COVID-19 response]. The sources
used for each of the EUA products are in Appendix 4: Nexis Uni, Company Web Pages, and
Google Sources.

Data Analysis
510(k) Downloadable Files
The information obtained from the files includes the 510(k) number, applicant, contact,
address, device name, date received, decision date, decision, advisory committee, product code,
type of submission, class designation, and review information. For this thesis, the following
categories were of focus: applicant, date received, decision date, and product code. The first step
I took was to filter the data for ventilator product codes that are currently marketed in the US,
these codes are listed in Table 6 (FDA EUA COVID-19, 2020). Next, I analyzed this data in
Tableau to visualize product approvals over time and the distribution of product codes prior to
the COVID-19 EUA.
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Table 6: Ventilator product codes with descriptions. Rows shaded in gray are most prominent throughout the analysis.

Product
Code
BSZ
BTL
BZD
CBK
MNS
MNT
NFB
NHJ
NHK
NOU
NQY
ONZ
QAV

Description
Gas-Machine, Anesthesia
Ventilator, Emergency, Powered (Resuscitator)
Ventilator, Non-Continuous (Respirator)
Ventilator, Continuous, Facility Use
Ventilator, Continuous, Non-Life Supporting
Ventilator, Continuous, Minimal Ventilatory Support,
Facility Use
Conserver, Oxygen
Device Positive Pressure Breathing, Intermittent
Resuscitator, Manual, Non-Self-Inflating
Continuous, Ventilator, Home Use
Ventilator, Continuous, Minimal Ventilatory Support,
Home Use
Mechanical Ventilator
High Flow/ High Velocity Humidified Oxygen Delivery
Device

Device
Class
II
II
II
II
II

Life Sustaining
Device
Y
Y
Y
-

II

Y

II
II
II
II

Y
Y

II

Y

II

-

II

-

Ventilator Background
There are two major types of ventilators, invasive and noninvasive. The basic
components of an invasive ventilator can be seen in Figure 1. These consist of the ventilator,
filters, expiratory and inspiratory limbs, a humidifier, and the endotracheal tube (Berlinski,
2017).

Figure 1: Diagram of a basic invasive ventilator (Berlinski, 2017)
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The basic components of a noninvasive ventilator can be seen in Figure 2. These consist
of the ventilator, inspiratory limb, expiratory limb or leak, humidifier, and a face mask
(Berlinski, 2017).

Figure 2: Diagrams of basic noninvasive ventilators. Top: dual-limb circuit. Bottom: single-limb circuit. (Berlinski, 2017)

Table 6 highlights the ventilator codes that are most prominent throughout this thesis.
These product codes are BSZ, BTL, BZD, CBK, and MNT. BSZ is an anesthesia machine that is
typically used during surgery. These devices can be used without anesthesia settings in
emergency situations such as COVID-19 to act as a normal invasive ventilator. BTL is a
powered emergency ventilator. These devices are typically compact and more simple to use,
making them commonly used in ambulances or in the field. BZD is a noninvasive respirator
device. This can be a variety of Positive Airway Pressure (PAP) machines such as continuous
(CPAP) and bilevel (BPAP). CPAP devices provide a continuous level of pressure while BPAP
devices can provide varying levels of pressure. BZD devices are typically used at home to treat
respiratory conditions such as obstructive sleep apnea. CBK is the typical invasive ventilator
used in intensive care units (ICU). MNT provides minimal ventilator support. This product is
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typically double coded with BZD and CBK products and can be used in a hospital or at home
and invasively or noninvasively.
EUA Company Characteristics
Data collected from the FDA “Ventilators and Ventilator Accessories EUAs” webpage
provided information on the date of authorization, manufacturer, product name, and device
description. Since the EUA only provided device descriptions, not product codes, I assigned
product codes to match the descriptions seen in the table above. Once product codes were
assigned, authorizations over time and the distribution of product codes were visualized in
Tableau. Additionally, I coded the data collected based on the categories in Table 7 to gain a
better understanding of companies that obtained EUA authorization.
Table 7: EUA authorized ventilators coding key

Variable
Product Code

Code
Table 6
0

Previous 510(k) Approvals
1
If no prior 510(k), was the
device approved/ in use in
another country?
Industry
Company Origin

Description
See table
No results in the 510(k) database
Search: [Company]
Results in the 510(k) database
Search: [Company]

0

No

1
0
1
0
1

Yes
Non-medical device industry
Medical device industry
Not U.S. based
U.S. based
Yes, company is not contained in the
downloadable 510(k) files
No, company is contained in the downloadable
510(k) files
Organization existing prior to COVID-19
concerns
Organization that appears to have been created
after COVID-19 concerns

0
New Player
1
0
New Organization
1
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Detailed EUA Ventilator Analysis
Using the data gathered from Nexis, company web pages, product brochures, and Google,
I completed a detailed analysis of each ventilator on the EUA list. This data was utilized to
identify information about unique properties of EUA products such as design, components, or
supply as well as similarities and differences in product designs. While data was collected, I
separated it into categories to allow for easy identification of themes. Some of the key categories
analyzed are listed in Table 8.
Table 8: Nexis and company webpage data categories

Categories
Product existence prior to
the EUA
Plans to pursue full FDA
approval
Product Development
Timeline
Design Goals
Components
Technology
Manufacturing
Supply Chain
Open Source
Cost
Partnerships
Notable Quotes

Description
Did the product exist prior to the EUA?
If yes, when was it developed? What is its intended use? Were any
modifications made?
Did the company mention plans to pursue FDA approval once the
EUA is invalid? What are the plans?
How long did the product take to develop?
What design goals did companies explicitly state?
What components did the company explicitly point out as unique or
innovative?
What technology did the company explicitly point out as unique or
innovative?
Did the company explicitly point out unique or innovative
manufacturing measures?
What supply chain aspects did the company explicitly point out as
unique or innovative?
Was the design open source?
How much did the product cost to build and/or how much will it
sell for?
Did the company partner with anyone?
If yes, what was the partner’s contribution?
Any notable quotes about innovation during COVID-19 or
measures taken for COVID-19 were recorded.
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Results
FDA Approvals and EUA Authorizations Over Time
This section will use the information obtained from the 510(k) releasable database and
the EUA authorized ventilators, to construct visuals to show approvals and authorizations over
time. Figure 3 shows the number of 510(k) submissions per year from 1976 to August 2020 that
resulted in an approved device. There is an overall increase in submissions from 1976 to 1986, a
stagnant period from 1986 to 2001, another rise from 2001 to 2012, then a drastic drop in
submissions from 2012 to 2020. There were 51 submissions in 2012, 10 submissions in 2019,
and 2 from January to August 2020. Submissions per year show a variable pattern with
alternating increases and decreases. Overall, submissions have shown an increasing trend, but the
steep decrease from 2012 to 2020 is prominent.
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Figure 3: Number of 510(k) submissions per year from 1976 to August 2020. The dark gray line is the sum of the individual
product codes.

Figure 4, shows the number of EUA authorizations per week from March 24th, 2020,
when the EUA was enacted, to August 23rd, 2020, when initial data collection for this thesis was
completed. Figure 4 shows the largest number of authorizations over the first 7 weeks, March
24nd to May 3rd. By May 10th, the number of authorizations decreased, this decrease remained
consistent through the end of the figure. There were a total of 77 authorizations over five months,
with 57 in the first two versus 20 over the following three months. Comparing Figure 3 and
Figure 4, 77 devices were approved through the EUA over five months versus 62 510(k)
submissions over the past four years and 86 over the past five.
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Figure 4: Number of EUA authorizations per week from March 24th, 2020 to August 23rd, 2020

510(k) and EUA Product Code Distributions
This section utilized the 510(k) releasable data along with EUA data obtained from the
FDA to analyze the focus in product codes before versus during the EUA. These distributions
can be seen in Figure 5. The most common ventilator products prior to COVID-19 were CBK,
BZD, and BSZ. These products made up 35.52 %, 31.04 %, and 13.66% of the approved
products from 1976 to August 2020, respectively. The most common products authorized for the
COVID-19 EUA were BTL – 37.66%, MNT – 28.57%, and CBK – 11.69%. The rise of the
MNT product code was large as this code only accounted for 1.42% of the products from the
510(k) database. As you may recall, BTL (ventilator, emergency, powered resuscitator), BSZ
(gas-machine, anesthesia), BZD (ventilator, non-continuous respirator), CBK (ventilator,
continuous, facility use), and MNT (ventilator, continuous, minimal ventilatory support, facility
use
32

510(k)

EUA

Figure 5: 510(k) distribution of product codes (left) and EUA distribution of product codes (right)
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EUA Company Make-up
This section shows the make-up of the companies that submitted EUA approvals. This
information can be seen in Figure 6. The three categories in this figure are New Organization –
organizations that appear to have been created after the increase in COVID-19 concern, New
Player – a pre-existing non-medical device organization (i.e., NASA, Fitbit, Virgin Orbit), and
Old Player – a pre-existing medical device company. There were 10 new organizations, 8 new
players, and 38 old players. 33 of the old players produced ventilator or respiratory related
products prior to the EUA. New organizations and players mostly submitted emergency
ventilators, BTL. The old players submitted a variety of product codes.

Figure 6: EUA company make-up with product code distribution

Pre-existing Devices Overview
The purpose of this section is to provide an overview of the devices on the EUA list that
existed prior to the EUA. This information was determined by searching the device in the 510(k)
database and on the company’s webpage. The full list of EUA products can be found in
Appendix 1: EUA Products. Additionally, there were 10 devices for which no data was found
and 5 devices that were repeated with no obvious modifications. These devices are listed in
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Appendix 2: Products with No Data Found and Appendix 3: Repeat Devices. For further
analysis, the 10 devices with no data and the 5 device repeats were removed from the ventilator
count leaving 62 products.
Table 9 shows four products that were on the market prior to the EUA, that did not make
any modifications to their devices for EUA authorization, and the intended use did not change.
These devices were utilized in other countries and did not have 510(k) approval. The EUA
authorized the device to be used in the U.S.
Table 9: EUA devices without modifications and no change in the intended use

Company

Product

510(k)
approval?

What is the
Intended Use?

Beijing Aeonmed

VG70 ventilator

No

Ventilation

Shenzhen Mindray
Biomedical

Mindray
SV300/SV600/SV800
Atlan A350 and Atlan A350
XL
Beijing Aeonmed
Shangrila510S

No

Ventilation

No

Ventilation

BSZ

No

Emergency
Ventilation

BTL

Dragerwerk
CMI Health

Product Code
Critical Care
Ventilator
Critical Care
Ventilator

Table 10 shows 12 devices that existed prior to COVID-19 and no modifications were
made to the device, but the intended use of the device changed for the EUA. This information
was determined by the data collected from company web pages. Seven of these devices were
approved in other countries and do not have 510(k) approval. One of these include the Luna G3
B30VT by 3B medical; attorney Gunawardhana, who helped 3B medical obtain authorization,
noted that “it is deeply rewarding to see a client with innovative thinking gain approval to help
with an issue that has become all too real for Americans” (Shook Hardy & Bacon, 2020, p. 1).
The other five devices do have 510(k) approval but the EUA was necessary to allow the devices
to be used to treat COVID-19 patients. The intended use for most of the devices is supportive
devices for people with restrictive lung disorders or obstructive sleep apnea (OSA). These types
of conditions are typically treated with positive airway pressure (PAP) devices.
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Table 10: EUA products without modifications with a change in the intended use

Company

Product

510(k)
approval?

RESMED

Lumis 150
VPAP ST

Yes

RESMED

Stellar 150

Yes

RESMED

AirCurve
ST

Yes

BMC Medical

Y-30T

No

BMC Medical

Luna BPAP
25A- LG3700

No

RESMED

AirCurve 10
ST-A

Yes

3B Medical Inc
Resvent
SLS Medical
Technology
Resvent Medical
Technology
Shenzhen Yamind
Medical Tech
SysMed (China)

What is the Intended Use?

Product
Code

No

Restrictive Lung Disorders,
Severe COPD, Hypoventilation
BiLevel Therapy
OSA
BiLevel Therapy
OSA
BiLevel Therapy
OSA/ respiratory insufficiency
BPAP system
OSA
BPAP system
Restrictive Lung Disorders,
Severe COPD, Hypoventilation
BiLevel Therapy
OSA
CPAP system
PAP system

No

CPAP system

BZD

No

PAP system

BZD

DM series

No

CPAP system

BZD

VM series

No

PAP system

MNT

Luna G3
B30VT
iBreeze PAP
CP101/CP101S
Series
iBreeze 30STA
device

Yes

MNT
MNT
MNT
MNT
MNT
MNT
MNT
MNT

Table 11 shows eight devices that existed prior to the EUA and contain modifications that
were made for COVID-19. These products were grouped in this table if an article from Nexis or
a company webpage explicitly stated that a modification was made to the device for COVID-19.
Modifications made to devices include the use of alternate components, maximizing efficiency,
modifying a device such as a CPAP into a ventilator, and adding a closed-circuit design with a
bacterial filter to the device.
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Table 11: EUA devices with modifications

Company

Product

VenTec Life Systems

V+Pro Emergency
Ventilator

Hillrom

MetaNeb 4

AutoMedX

SAVe II Series Ventilator

Wilcox Industries Corp

Wilcox PATRIOT SAVR
(Amended July 21, 2020)

Somnetics International

Transcend 3 BiPAP

NeoNatal Rescue

AdultLife Pro Ventilator

Breas Medical

Z2 Bilevel

Hillrom

Life 2000 Ventilation
System Product No. BTV5

Modification
Redesigned the device
with alternate
components
Modified to a closedcircuit design using a
bacterial filter to reduce
cross contamination
and aerosolized
particles
Made performance
modifications to
maximize efficiency for
COVID-19
Modified for COVID19, previous was a
large backpack,
redesigned to make it
smaller and more
portable
Repurposed CPAP into
BiPAP machines
Modified their infant
ventilator for adult use
CPAP modified to
ventilator
Modified a noninvasive
device for invasive use

Product Code
CBK

NHJ

BTL

BTL

BZD
BTL
MNT
CBK

Detailed EUA Ventilator Findings
This section utilizes data collected from Nexis, company web pages, product brochures,
and Google to provide a comprehensive summary of notable findings. First, the overall design
goals are analyzed. Next, areas where innovation occurred were analyzed further, such as supply
chain, manufacturing, and unique components as well as whether the innovative measure was
taken by a new organization, new player, or old player.
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Design Goals
This section provides a summary of the design goals identified by companies. Design
goals between companies were similar. The most common goals were:
•

Portable

•

Affordable

•

Simple to use

•

Easy to maintain

•

Minimal components

•

Easy to manufacture

These goals were determined in response to the situation imposed by COVID-19. Some
of the goals revolve around the usability of the device. An example of this is from AutoMedX
who stated, “the idea was to make something simple that could be easily deployed by medics in
high-stress environments” (AutoMedX, 2020). The other goals revolve around designing a
simple device that allows for rapid, large scale production. Philips is a company that had
ventilators on the market prior to COVID-19, but they created a new ventilator for the EUA that
was “designed for mass production” (Philips, 2020). The design goals identified relate to the
sources of innovation that will be explained in the next section.
Innovation Findings Summary
An overview of sources of innovation and innovative solutions can be seen in Figure 7.
There were four main sources of innovation identified in this paper, intended use, supply chain,
manufacturing, and components/ technology. The devices that fall under intended use are
identified in Table 10. Various PAP machines altered their intended use definition to treat
COVID-19 patients. There were 17 companies that mention innovation in the supply chain, 15 in
manufacturing, and 45 in components and technology. The detailed findings from these branches
are seen in the following sections.
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Figure 7: Summary of innovative solutions as identified in publicly available information. The dark blue arrows represent
company count. Colored arrows represent product count. Products can appear more than once so numbers under individual
branches may not add up to the root branch.

Components and Technology
The component and technology innovations were split into two categories based on the
nature of the innovation. The first category are features that were used in ventilators before the
EUA, but the products below added them to their design, this can be seen in Figure 8. The
second category, seen in Figure 9, are features that are less common or unique to the ventilator
industry.
Two of the most common components that were emphasized in EUA devices were the
addition of certain filters to breathing circuits such as high-efficiency particulate air (HEPA)
filters and the ability for the device to be powered by a battery. Four companies mentioned the
addition of autoclavable valves. Lanick Med Systems stated that their device, Lyra x1, contains

39

an “innovative expiration valve disassembling concept that brings more ease and efficiency to
the sterilization process” (Lanick, n.d.).

Filter (type)
•
•
•
•
•

Y-30T
Luna BPAP 25A
pNeuton (bacterial)
E30 (bacterial / viral)
SAVe II (HME /
bacterial)
• Luna G3 BPAP
• Panther 5 (standard)
• AdultLife (HEPA)
• Go2VENT
(HEPA/HME)
• Covid Ventor (viral)
• AustinP51 (HEPA)
• Venti-Now (HEPA)
• PREVENT (HEPA)
• Pneumatic Resuscitator
(HEPA)

Battery Power
• LTV Models
• MTV1000
• V+Pro
• Model 6000a, T5, T7
• AdultLife
• V2O Sagico
• Ventway Sparrow
• Puritan Bennet 560
• SAVe II Series
• JIXI H-100
• Panther 5
• WorldVent
•AustinP51

Autoclavable Parts
(type)
•VG70 (metal exhalation
valve)
•SV Series (inspiration
valve)
•Lyra x1 (expiration valve)
•Panther 5 (outlet and
exhalation valve)

Figure 8: Features added to EUA products. Products in italics were developed by a new organization or player.

Figure 9 shows the products that implemented newer technology and solutions in their
EUA devices. The first set of technology is remote access. Six devices mention the
implementation of a remote access system, two of them stem from a new organization or player.
Remote access was implemented differently in each device including the use of a removable
tablet, remote control, and Wi-Fi access. ResMed mentioned that they had big plans in digital
health prior to COVID-19 and the pandemic brought some of their innovations to surface earlier
than expected (ResMed, 2020). Four products focused on software to enhance the usability of the
device. These ranged from incorporating artificial intelligence (AI) to programmable computer
logic that enables the device to self-calibrate. Two products used innovative air processing
technologies. Vayu created an innovative air blender that does not require a compressed air tank,
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they perceive their device as “an ultra-low cost, disruptive innovation to address the world’s
most pressing health challenge” (Vayu, 2020). Not only was Vayu’s solution innovative, but the
approach they took was unique as well. Vayu designed their bCPAP device as a neonatal
solution because 80% of the ventilators utilized in the NICU are full-service ventilators. With
this solution, these full-service ventilators can be used to treat adults with COVID-19 (Vayu,
2020). Two devices took a modular approach to their design, which allows parts to be swapped
based on availability and location of use. Finally, ten products pursued an automated bag valve
mask (BVM) design, these were all made by new players and organizations. BVM’s were also
used as a response to supply chain innovation.
Remote Access
•
•
•
•
•
•

ResMed Products
VX850
Puritan Bennet 560
Panther 5
X-Vent
UMV-001 EUA

Software
•nHale BiPAP: AI, intelligent
factory control (IFC)
•X-Vent: programmable
computer logic (PLC), selfcalibrating
•MVM: focus on software, kept
hardware minimal
•Model 6000S, T5, T7:
innovative voice guided
direction

Modular Design
• MVM: modular design allows parts to be
swapped
•CoroVent: electricity type, gas
connections, and language can be
modified for areas around the world

Automated BVM
•
•
•
•
•
•
•
•
•
•

Pneumatic Resuscitator
Spiro Wave
AustinP51
Venti-Now
LifeMech A-VS
PREVENT
Coventor
Virgin Orbit Resuscitator
Fitbit Flow
Apollo ABVM

Air Processing Technology
• Vayu bCPAP: innovative air blender
• Panther 5: advanced blower

Figure 9: Unique features of EUA products. Products in italics were developed by a new organization or player.
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Supply Chain
Some aspects of EUA products that are innovative stem from the supply chain, including
how and where components are sourced. Most of the innovation in the supply chain took place
with new organizations and players.
Table 12 shows unique supply chain features that were mentioned by new organizations
and players. New organizations and players were the only ones that sourced bag valve masks
(BVM) for their products, there were 10 products that did this. These companies chose to utilize
a component that would be readily available in a hospital due to the equipment shortage from
COVID-19. Virgin Orbit is one of these companies and stated the importance of “sharing ideas
across a broad national and international network to accelerate progress on solutions to this
equipment shortage” (Virgin Orbit, 2020, p. 1). Two of the companies utilized components that
can be made with do-it-yourself (DIY) techniques such as 3D-printing, metal stamping, and
modifying consumer goods. Another common method used to source materials was the use of off
the shelf and globally available components.
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Table 12: Supply chain features of new organizations and players

Company

Classification

Product

SecondBreath

New Organization

Pneumatic Resuscitator

Spiro Devices
Air Boost

New Organization
New Organization

Spiro Wave
AustinP51

Venti-Now

New Organization

Venti-Now Resuscitator

World Ventilator
Foundation

New Organization

WorldVent Ventilator

LifeMech

New Organization

LifeMech A-VS

MICo Medical

New Organization

CoroVent

PVA

New Player

PREVENT

University of
Minnesota Medical
School

New Player

Coventor Adult Manual
Resuscitator Compressor

Virgin Orbit

New Player

Fitbit
Stewart & Stevenson
Healthcare

New Player

Virgin Orbit
Resuscitator
Fitbit Flow

New Player

Apollo ABVM

NASA Jet Propulsion
Laboratory

New Player

VITAL Ventilator

Elemaster
Technologie
Elettroniche

New Player

Mechanical Ventilator
Milano (MVM)

Supply Chain
Commercially available
materials
BVM
BVM
BVM
Off the shelf medical grade
components
BVM
Design based on common
consumer electronics
Key components have
multiple sources.
Globally available
components
BVM
EU sourced components
PVA makes every
component except the
circuit board
BVM
frame can be metalstamped, 3D printed, or
modified consumer goods
BVM
BVM
BVM
DIY Components
BVM
Utilizes materials outside of
the traditional ventilator
supply chain
Off the shelf components
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Table 13 shows the supply chain features of old players. Old players attempted to combat
the component shortage by utilizing a partner’s supply network.
Table 13: Supply chain features of old players

Company
Covidien
VenTec Life
Systems
Philips
Respironics

Product
Puritan Bennett 560
Ventilator System
V+Pro Emergency
Ventilator
E30 ventilator

Supply Chain
Partner’s supply - PCBA circuit boards from intel
Partner’s supply - Sourced parts and assemblies by utilizing
GM’s supply network
Partner’s supply - Sourced parts and assemblies by utilizing
Flex and Jabil’s supply networks

Manufacturing
Another way innovation played a part in the production of EUA devices was through
manufacturing. Innovative manufacturing approaches were split between new organizations and
players and old players.
New organizations and players were the only companies that mentioned designing for
manufacturability. Companies mainly approached this by minimizing components. Spiro
Devices was one of the companies that took this approach, “like so many other measures granted
EUA, this may not be an ideal replacement for FDA-approved equipment, but it’s an innovative,
scalable solution that could mean big differences in the level of care at overburdened healthcare
facilities” (Etherington, 2020, p. 1). Other approaches included redesigning an existing
manufacturing facility and partnering with other companies, which can be seen in Table 14.
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Table 14: Manufacturing features of new organizations and players

Company

Spiro Devices

Classification
New
Organization

Product

Manufacturing

Spiro Wave

Design for manufacturability

World Ventilator
Foundation

New
Organization

WorldVent
Ventilator

PVA

New Player

PREVENT

University of
Minnesota Medical
School

New Player

Virgin Orbit

New Player

NASA Jet
Propulsion
Laboratory
Elemaster S.p.S.
Technologie
Elettroniche
Nanotronics
Imaging

Coventor Adult
Manual Resuscitator
Compressor
Virgin Orbit
Resuscitator

Design for manufacturability low component counts and
minimal dynamic performance
requirements
Retooled their manufacturing
facility
Partner - Boston Scientific
Design for manufacturability

New Player

VITAL Ventilator

Design for manufacturability

New Player

Mechanical
Ventilator Milano
(MVM)

Design for manufacturability reduced number of parts

New Player

nHale BiPAP

Innovative manufacturing
vision to quickly build and
scale the device

The main approach old players took was to utilize partnerships. Some partnerships
occurred between a medical device company and a non-medical device company such as VenTec
Life Systems and General Motors (GM) or GE healthcare and Ford. VenTec Life Systems stated,
“this partnership is a historic effort and a great reminder of what can be accomplished with the
power of American innovation and American manufacturing skill uniting together around a
singular mission to save lives” (VenTec Life Systems, 2020). Additionally, companies reworked
typical work routines. Dragerwerk commented on the approach they took, “We have agreed with
our employees on innovative work organization and working time models. This gives us the
necessary flexibility to respond to the high volume of orders” (Drager, 2020). Table 15
summarizes the manufacturing approaches taken by old players.
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Table 15: Manufacturing features of old players

Company
Vyaire Medical

Product
LTV2 model 2200 and LTV
model 2150

Inovytec

Ventway Sparrow

GE Healthcare

pNeuton Model A-E Ventilator
Puritan Bennett 560 Ventilator
System
MTV1000 ventilator

Covidien
MEKICS
VenTec Life
Systems

V+Pro Emergency Ventilator

Dragerwerk

Evita and Babylog Devices

Manufacturing
Partner - Spirit Aerosystems
Converted part of their missile
production line
Partner - Ford
Partners - Baylis Medical, Foxconn
Technology Group, and Vingroup
Partner - Biolase
Partner - GM
Redesigned production line
GM redesigned their manufacturing
process
Innovative working time models

Partnerships and Collaboration
Partnerships were another tool that was utilized for many EUA devices that helped drive
the innovative measures mentioned above. Table 16 and Table 17 show partnerships where
specific contributions were mentioned. There were other companies that mentioned partnerships
but did not comment on who the partner was and/or how they contributed to product
development. Figure 10, shows an overview of the various types of partnerships and
collaborations that occurred for the EUA. In the sections above, partnerships were mentioned as
a source of innovation in the supply chain and manufacturing branches. There were also
partnerships that helped with design, testing, and FDA facilitation. Partnerships ranged from
aerosystems, automobile companies, government, universities, hospitals, doctors, and even
patients. FDA commissioner Stephen Han stated “fighting the virus and treating patients during
this unprecedented global pandemic requires innovative approaches and action. It also takes an
all-hands-on-deck approach, [NASA’s VITAL device] shows what we can do when everyone
works together” (NASA, 2020). Another term mentioned along with partnerships was
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collaboration and the importance of interdisciplinary collaboration to spark innovation. Fitbit
stated that their device “is a great example of the incredible innovation that emerges when
academia and industry employ problem-based innovation to respond quickly to an important
need” (Fitbit, 2020). LifeMech was also surprised by the innovation spurred by COVID-19, “it’s
interesting how this cross-platform collaboration, from people who have never really designed or
worked on a medical device, leads to something innovative. I think this goes to prove that there
are no limits to innovativeness, and you can actually do things differently. So, you've got an
engineer in Germany working with somebody out of their garage in Northern California, and at
the end of the day, we would just integrate that data together” (LifeMech, 2020).

Figure 10: Partnerships between the original authorized company and other industries and how those industries contributed. The
number represents the number of companies that mentioned a partnership with that industry.
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Table 16 shows the types of partnerships new organizations and players utilized. Seven
out of nine of these companies worked with someone who was able to help with the design of the
device. Partnerships for manufacturing, supply, funding, and distribution were also utilized.
Table 16: Partnerships utilized by new organizations and new players

Classification
New
SecondBreath
Organization
Company

Venti-Now

Enexor
BioEnergy

MICo
Medical
University of
Minnesota
Medical
School
Corporation
PVA
NASA Jet
Propulsion
Laboratory
Nanotronics
Imaging
Stewart &
Stevenson
Healthcare

New
Organization

New
Organization
New
Organization
New Player
New Player
New Player

Partner
UH anesthesiology
Senator Portman
2 BME students from University of
Cincinnati
UC Health, Cincinnati Children’s
Hospital, P&G, and Your Encore
Medical professionals - critical care
physicians, respiratory therapists
Schneider Electric, Casco Systems,
Border States Electric
Wolfe Industrial
Nemo Design
Several Czech companies
Korean heavy industry development co.

Contribution
Design and Testing
FDA Facilitation

Provided Steel Parts
Branding/ Marketing
Design
Distribution

Medtronic
Boston Scientific
UnitedHealth Group

Development
Design and
Manufacturing

National Grid
STARK Industries
Perioperative and Pain Medicine at Mount
Sinai

Funding

Design
Design
Control System

Manufacturing
Testing

New Player

Northwell Hospital Emergency Physicians

Design

New Player

Oshman Engineering Design Kitchen at
Rice University

Design
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Table 17 shows partnerships utilized by old players. Ten out of twelve old players
partnered with another company for manufacturing assistance. Others used partnerships for
design, funding, supply, distribution, and EUA assistance.
Table 17: Partnerships utilized by old players

Company

Partner

Vyaire Medical

Spirit Aerosystems

RESMED

Inovytec

GE Healthcare

Covidien

MEKICS Co
VenTec Life
Systems
Philips Respironics
3B Medical
AutoMedX
NeoNatal Rescue
VORTRAN
Medical
Technology

Government, Health Authorities, Hospitals,
Physicians, and Patients
Directorate of Production and Procurement,
Directorate of Defense Research and Development
at the Defense Ministry and Israel Aerospace
Industries (IAI)
Ford Motor
Airon
Baylis Medical, Foxconn, Vingroup
SpaceX
Intel
Celestica
Biolase

Contribution
Manufacturing and
Supply
Design

Funding/ Manufacturing
Manufacturing
Design
Manufacturing
Valve build
PCBA board source
Subassembly production
Manufacturing and
Distribution

General Motors

Manufacturing

Flex (Trilogy) and Jabil (V60)
Attorney Sonali Gunawardhana
NCA
ATL
Local Respiratory Therapists

Manufacturing
EUA assistance
Manufacturing
Manufacturing
Design

Xerox

Manufacturing
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Other
This section provides additional information that was found during data collection. The
information includes the cost of the EUA devices, open-source designs, and plans to pursue full
FDA approval.
EUA Product Costs
Product cost was not available publicly for many of the products, but some products
mentioned price ranges or estimated cost in reference to a traditional ventilator. A traditional
ventilator costs between $25,000 - $50,000, this estimation was supported by multiple articles
throughout the analysis (Glass, 2019). Table 18 shows some products along with their cost. The
cost of devices varies significantly even within the same product code. The devices submitted by
new organizations and players generally cost less. One exception goes to Vayu, whose mission is
to create disruptive healthcare solutions (Vayu, 2020). Vayu’s device has the lowest cost, $120.
Additionally, old players typically did not mention prices, so there are only three old players in
the table below. More than half of the new organizations and players mentioned a price or price
estimate.
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Table 18: EUA product cost

Company
SecondBreath
Spiro Devices
Venti-Now
Air Boost
MICo Medical
Enexor
BioEnergy
Nanotronics
Imaging
University of
Minnesota
Medical School
PVA
Stewart &
Stevenson
Healthcare
Beijing
Aeonmed

Classification
New
Organization
New
Organization
New
Organization
New
Organization
New
Organization
New
Organization

Product
Pneumatic
Resuscitator

Product Code

Product Cost

BTL

1/3 the usual cost

Spiro Wave

BTL

Cost to build: Less than
$5,000

Venti-Now
Resuscitator

BTL

Less than $5,000

AustinP51

BTL

$1,500

CoroVent

BTL

X-VENT

BTL

New Player

nHale BiPAP

MNT

A fraction of the cost

New Player

Coventor

BTL

Cost: $1,000
Cost to build: $150

New Player

PREVENT

BTL

$6,000 - $8,000
(1/5 the cost of a traditional
ventilator)

New Player

Apollo ABVM

BTL

Target price is under $250

Old Player

VG70 ventilator

Critical Care
Ventilator

Original Cost: ~ $50,000
EUA Cost: $12,000 - $17,000

CBK

$10,000

CPAP

Cost to build: Less than $120

Covidien

Old Player

Vayu Global
Health

Old Player

Puritan Bennett
560
Vayu bubble
CPAP

3x less expensive,
$9,500 – $12,000
Costs 50% less than most
ventilators

Open-Source Designs
Another solution that appeared multiple times was the use of open-source designs. Table
19 below shows the EUA authorized open-source designs. All five of the open-source designs
were submitted by new organizations (1) and new players (4).
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Table 19: Open-source designs

Company
LifeMech
University of Minnesota Medical
School
NASA Jet Propulsion Laboratory
Elemaster S.p.S. Technologie
Elettroniche
Stewart & Stevenson Healthcare

Classification
New
Organization
New Player
New Player
New Player
New Player

Product
LifeMech A-VS
Coventor Adult Manual Resuscitator
Compressor
VITAL Ventilator
Mechanical Ventilator Milano
(MVM)
Apollo ABVM

Plans to Pursue FDA Approval
Lastly, data was collected on companies’ plans to obtain full FDA approval, which would
allow their device to stay on the market after the COVID-19 EUA is withdrawn. There are nine
devices that plan to get full FDA approval, these devices can be seen in Table 20. Three of these
devices existed prior to the EUA. One company did not have FDA approval on their device in
the U.S. The other two companies are pursuing approval for modifications they made for
COVID-19. Wilcox Industries did not explicitly state that they were pursuing full approval, but
they did get a patent on their modified device which may infer they have plans for it to be
approved. NeoNatal Rescue modified their neonatal ventilator to be used for adults and they plan
to pursue approval for their new AdultLife Pro ventilator. Additionally, there are six companies
with new devices that stated they are interested in or have already started the regulatory process.
Three of these utilized BVMs in their designs and the other three created compact emergency
ventilator designs. Eight out of the nine devices in Table 20 fall under the emergency ventilator
product code, BTL.
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Table 20: EUA products planning to pursue FDA approval

Company
CoLabs
Spiro
Devices
Enexor
BioEnergy
LifeMech

Classification

Product

Product
Code

New
device?

Plans to get full FDA
approval?

New
Organization
New
Organization
New
Organization
New
Organization

COVID
Ventor

BTL

Yes

Yes

Spiro Wave

BTL

Yes

Yes

X-VENT

BTL

Yes

Yes

BTL

Yes

Yes

BTL

Yes

Yes

BTL
Critical
Care
Ventilator

Yes

Yes

No

Yes

No but was
modified
for EUA.
No but was
modified
for EUA.

Not stated but a patent was
obtained for the
modifications.

MICo
Medical

New
Organization

PVA

New Player

Vyaire
Medical

Old Player

Wilcox
Industries
Corp

Old Player

NeoNatal
Rescue

Old Player

LifeMech
A-VS
MICo
Medical
CoroVent
PREVENT
LTV
Models
Wilcox
PATRIOT
SAVR
AdultLife
Pro
Ventilator

BTL

BTL

Yes
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Discussion
This section will start by discussing the results obtained from the releasable 510(k)
database. Next, an overview of the EUA results will be compared to the 510(k) results to identify
the result of decreased regulatory barriers from the EUA on product submissions and types of
ventilators produced. Finally, detailed EUA findings and the nature of innovation will be
explained.

Ventilator Product Approvals Over Time
The results from FDA approvals and EUA authorizations showed a notable drop in
510(k) product submissions from 2012 to 2020. There are too many variables involved to assign
a known cause to the drop. For example, it may be that entry into the database by the FDA is
delayed. It is still worth noting as a possible indication that there was a lack of innovation in
ventilator technology prior to the pandemic. On the other hand, when the FDA enacted the EUA,
there were 77 device authorizations within five months, which is equivalent to the 510(k)
submissions that occurred over the past four to five years. While the EUA authorization is
temporary and is meant to stimulate new products and intended uses to help a national health
crisis, this uptick in EUA devices is notable. It signals that regulatory barriers may be one of the
factors inhibiting innovation.

Change in Product Code Focus
The 510(k) releasable data and products submitted to the EUA showed a change in
product code focus. Before the EUA, CBK (ventilator, continuous, facility use) and BZD
(ventilator, non-continuous respirator) were the most common products being developed, making
up 66.56% of the ventilators from 1976 to 2020. Under EUA authorizations, BTL (emergency
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ventilator) and MNT (minimal ventilatory support) were the most common, making up 66.23%
of EUA devices. BTL rose from 7.16% prior to and 37.66% during the EUA. MNT rose from
1.42% prior to and 28.57% during the EUA. BTL’s increase aligns with what would be expected
as emergency ventilators are typically less complicated and easier to develop in a time of
emergency. MNT appeared to rise with the change in the intended use of PAP devices. Most
COVID-19 patients do not need full ventilatory support, and MNT is a noninvasive option. The
shift in product code distribution indicates a likely increase in demand for innovation within
these device categories.
Additionally, one factor that may have contributed to the shift in focus in product codes is
the make-up of the companies that submitted devices to the EUA. There were eight new players
and ten new organizations that submitted devices to the EUA. Seventeen of these companies
submitted emergency ventilators. If these new players did not enter the industry, then the
emergency ventilator distribution would have only increased by 8.42% instead of the 30.5%
increase we saw in the findings. As we saw in the literature review, early-stage innovation
typically stems from new entries to the market. Innovation tends to increase when new players
and organizations enter a field because they typically enter to fill a need that has not been met.
There are no preconceived ideas or processes that may unintentionally limit innovation. In the
next part of the discussion, I will discuss the motivation for innovation during COVID-19.

Motivation for Innovation
Innovative solutions created in response to COVID-19 were centered around three main
issues. The first issue is the ventilator supply chain. Typical ventilator components were in short
supply and shipping delays made it difficult to obtain parts from inside and outside the United
States. This motivated companies to create designs with minimal components and to use
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alternate components over typical ventilator components. Additionally, The EUA for ventilators
was not enacted until two months after COVID-19 was declared a public health emergency. By
the time the EUA was enacted, the concerns of a ventilator shortage were high. Because of this,
companies wanted to produce as many ventilators as they could, as quickly as possible. They did
this by making their designs simple and easy to build to enhance manufacturability. Lastly,
companies that designed ventilators for the COVID-19 EUA focused on the usability of the
devices. Current ICU ventilators are difficult to use, so new designs needed to be as intuitive as
possible to ensure ease of use for medical personnel. Furthermore, ventilators were designed to
be portable and affordable to fill the needs of thousands of hospitals throughout the United States
and internationally. The design goals imposed by the constraints of COVID-19 led companies to
create innovative ventilators that could rapidly fill these needs. In the next part of the discussion,
I will go into more detail about how new players and new organizations contributed to
innovation.

Innovation from New Organizations and New Players
New organizations and players (companies that started after the rise in COVID-19
concern and pre-existing non-medical device companies, respectively) made up 25% of the EUA
devices and 32% of companies that submitted to the EUA. This makes up a substantial amount
of the EUA approvals and may indicate that barriers in the medical device industry inhibit new
entry and, therefore, innovation. Throughout the analysis, some patterns were seen in the
innovative measures pursued by new organizations and players. These companies had to create
ventilators in the face of many constraints created by COVID-19. In order for new ventilator
designs to have a positive contribution, typical supply chains and designs of ventilators needed to
be reevaluated.
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As mentioned in the findings, ten of the products incorporated the automation of a
manual breathing bag. The concept of implementing an automated BVM has been studied before
in the medical device industry as a solution to combat fatigue in EMS workers and as a realistic
solution for low-resource hospitals (Williams, 2019). While this design concept has been studied,
it has not been widely adopted. New organizations and players were the only companies that
used BVMs in their designs. This approach makes sense because new players probably do not
have a lot of experience with ventilators and ventilator designs, if any. Automating a BVM can
be executed quickly and utilizes supplies that are readily available in hospitals. Three of these
companies are planning to pursue full FDA approval.
The other eight products by new players were seven compact emergency ventilator
designs and one BPAP device. These products, along with the BVM designs, utilized off the
shelf, globally available, and even 3D printed components. New players needed to be innovative
with materials used to build the ventilators due to the strained ventilator supply chain. The
utilization of readily available components was also prominent in open-source designs. All five
of the open-source designs were created by new organizations and players. The use of readily
available components allows for these designs to be reproduced more easily by others. These
designs were all accessible online, allowing anyone to help the crisis. Open-source designs
facilitate open innovation by allowing knowledge to travel across endless sources for nonmonetary reasons (Chesbrough, 2020). Three other EUA devices that were not open source noted
that they gained their inspiration from open-source devices. While open-source designs may not
be a permanent solution to innovation in the medical device industry, they can lead to additional
innovative solutions.
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In addition to taking a unique supply chain approach, new organizations and players were
the only companies that intentionally designed their device to increase manufacturability. These
companies were looking to make their devices as simple as possible so they could be produced
and distributed rapidly. Companies did this by minimizing components, which was also able to
help drive the cost of the products down.
New players were able to implement various unique component and technology elements
into their designs. The more common features included in products were the addition of filters to
the breathing circuit and battery power use. Filters help decrease transmission of the disease, and
batteries allow devices to be portable, which is crucial when hospitals are over capacity, and
makeshift hospital set-ups are in use. Five companies integrated newer and novel technologies
into their design. This ranged from remote access to software features to modular designs. Two
out of the five companies used modular designs, while the other three chose to focus on
enhanced software features. The modular designs allow parts to be swapped based on availability
and location of use, which increases ventilator accessibility. The software innovations allow the
ventilators to be simple to manufacture and use.
While new players and organizations were able to take a plethora of innovative
approaches to design, they could not do it alone. Since they were new to the industry, many of
them partnered with someone that could help with the design. These partnerships ranged from
doctors and patients to medical device companies. Additionally, some companies utilized
partnerships for funding, device testing, device manufacturing, and FDA facilitation. Overall,
new players contributed to a variety of innovative solutions for the COVID-19 EUA.
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Innovation from Old Players
Innovative measures taken by old players (pre-existing medical device companies) were
different than those taken by new players. 33 of the old players created ventilators and
respiratory-related devices prior to COVID-19, and five did not. Some of the old players
obtained authorizations for devices that have been approved in other countries and did not
change the intended use, others may or may not have had 510(k) approval but needed the EUA to
alter the intended use of the products, and the last set of pre-existing devices were modified for
the EUA.
As seen in the findings, four EUA devices did not exhibit innovation due to the EUA.
These are the devices that existed before the EUA, were previously used in another country, and
did not alter the intended use for the EUA. The purpose of the EUA for these four devices was to
allow them to be used in the U.S. under their correct intended use.
The next set of devices showed innovation by changing the intended use. Changing the
intended use builds on prior knowledge of the device’s technology to repurpose its application,
which relates to the concept of rapid innovation discussed in the literature review (Von Krogh,
Kucukkeles, & Ben-Menahem, 2020). There were 12 devices submitted to the EUA that did not
modify their physical device, but the EUA allowed a temporary change in the intended use. The
devices under this category exhibit innovation because new knowledge was gained in how the
device works and how it can contribute to the medical field. The change in intended use occurred
with devices typically used for people with lung disorders or OSA. Based on the effectiveness of
these devices treating patients with COVID-19, this innovation may open a new intended use
post COVID-19; these devices can not only be used for respiratory disorders, but for respiratory
diseases as well.
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Eight devices approved through the EUA were existing approved devices with
modifications. This shows innovation because companies needed to reevaluate and rework their
devices to fit a different need. They utilized some resources and components they had on hand as
well as incorporated alternate components due to supply shortages. Product designs were also
modified to increase safety when treating a person with a viral disease. These types of changes
may be useful enough to be a permanent modification to the device or provide inspiration for
new devices.
Modifications to these pre-existing devices were executed rapidly, which brings an
interesting point to surface. For modifications such as maximizing performance efficiency, using
alternate components, and increasing portability, were companies aware of and planning to
pursue these changes before the EUA? If not, this indicates that the pandemic was the main force
behind these innovations and the reduced EUA barriers allowed them to be executed quickly.
There is also a possibility that companies were aware of these changes before the EUA and may
or may not have intended to pursue them, but the EUA allowed them to get FDA approval,
although temporary, in a quick manner compared to the traditional FDA process. This could
indicate that the current regulatory process inhibits innovation as companies are aware of
changes that would improve their devices but are not implementing them under the typical
regulatory process.
Old players did not indicate that they made many changes to their supply chain. Only
three companies mentioned something in this area, and they all took the same approach utilizing a partner’s supply network to compensate for the shortage of supplies. A similar
approach was taken for manufacturing. Five companies mentioned utilizing partners to help
manufacture their products. Another company implemented innovative working time models to
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facilitate manufacturing. While the specific actions taken were not stated, if this model is
executed well, it could have a lasting impact on the company’s manufacturing processes.
The components and technology utilized by old players were centered around adding
filters, battery power capabilities, and autoclavable parts into their designs. These additions made
the devices more suitable for use during COVID-19 but did not fundamentally change the design
of the ventilators. Two of the old players that did not have ventilator products prior to the EUA
were able to integrate innovative air processing technologies into their ventilator designs. These
two devices were solutions to the shortage of compressed medical air, as these new air
processing technologies can run without compressed air. Advanced air processing technology
also allowed their devices to be more affordable, one of them being Vayu’s disruptive innovative
solution to the ventilator industry at $120 (Vayu, 2020). The other innovative approach taken
was the incorporation of remote access to ventilator devices. This feature allows medical
personnel to control the ventilators from outside of the room which limits the chance of disease
transmission and allows medical professionals to monitor multiple patients at a time. Remote
access is an example of a technology that was capable of being implemented prior to COVID-19,
but there was no incentive to create devices like this. COVID-19 accelerated the use of this
technology in the medical field and the EUA allowed it to be implemented quickly. This is a
technology that would be useful to medical personnel outside of pandemics as well.
Partnerships were utilized by old players just as much as new players and organizations.
Most of the old players partnered with a company that could help with manufacturing
capabilities. This makes sense as medical device companies typically make devices to order, so
their manufacturing facilities are not built for mass production (Farrugia & Plutowski, 2020).
Partnering with other medical device companies and automobile companies allowed production
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to be ramped up for these devices. Less common partnership contributions include funding and
design. Old players took various approaches to the COVID-19 EUA, but most of them focused
on small changes to existing devices rather than novel changes.

Nature of Innovation
This section will discuss the nature of innovation from the EUA authorized products.
Most early-stage innovations, such as innovation from the components used to build the device,
device design, and technology incorporated, stemmed from new organizations, new players, and
old players who were not in the ventilator industry. This finding of early-stage innovation
occurring in new players aligns with what was seen in the literature review. The barriers to small
firms and new players may significantly impact the amount and type of innovation in the medical
device industry. The EUA allowed these new players to enter the medical device industry and
implement their innovative solutions with minimal risk.
Old player’s innovation typically stemmed around late-stage product development. Few
of the devices had fundamental design changes, and the ones that did design came from medical
device companies from outside the ventilator industry. Most did not have any change or a change
in intended use and some type of modification. A newer technology that old players from the
ventilator industry pursued was implementing remote access into ventilator devices. The
COVID-19 EUA may have helped old players implement an emerging technology that would
have taken longer to approve otherwise, such as remote access.
While there were types of innovation that were unique to new organizations and players
versus old players, there was some overlap. Both utilized partnerships to help execute
production. Partnerships can best contribute to innovation when people are working towards a
common goal and sharing knowledge openly. These partnerships may have opened the door for
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future collaborations when the nation is not in a time of crisis, or these partnerships may enable a
quick reaction time in the event of another pandemic or global crisis.
There were many innovative solutions identified throughout this analysis and the
motivation behind these relates to the concept of frugal innovation. Frugal innovation is “doing
more, with less, and being creative, innovative, and resourceful in the face of institutional voids
and resource constraints” (Harris, Bhatti, Buckley, & Sharma, 2020). Frugal innovation is at the
forefront of solutions utilized during a global pandemic. During COVID-19, there has not only
been a shortage of medical device supplies and components, but delivery and production
capabilities were limited due to essential working constraints such as social distancing.
Additionally, companies needed to figure out how to make things quickly for less money to keep
up with rising COVID-19 cases and ensure hospitals could afford an adequate supply of
ventilators.
Frugal innovations can be seen in the supply chain, manufacturing, and components/
technology. Due to the shortage of medical supplies, companies that submitted new solutions to
the EUA needed to be innovative with their components. Companies took various approaches to
deal with this issue, such as utilizing their partners’ supply network, using off the shelf or
commercially available materials, sourcing materials from outside the medical supply chain,
using DIY components, and using materials already present in hospitals such as manual bag
masks. These solutions helped relieve the burden on the typical ventilator supply chain, and the
different approaches minimized the risk of companies running into a shortage again. Additional
examples of frugal innovation also appeared through components and technology used. Many
companies designed solutions that require fewer components and are easier to build to help the
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supply chain issue and enhance the product’s manufacturability. Overall, multiple solutions
stemmed around frugal innovation due to the circumstances of COVID-19.
In summary, innovation has occurred as a result of the COVID-19 EUA. This innovation
stemmed in different ways, from the supply chain to manufacturing, to product design. The
different areas of innovation allowed for an increased number of feasible solutions to the
ventilator shortage.
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Conclusion
Innovation in the medical device industry is crucial to meet the constantly changing
needs of society. As identified in the literature review, innovation in the medical device industry
has been slow and met with barriers from the regulatory process, but many people said
innovation was soaring as a response to COVID-19 (Woolliscroft, 2020). COVID-19 opened a
unique opportunity to explore innovative measures pursued under a process with reduced
regulatory barriers, the EUA. This thesis looks in detail at the level and types of innovation that
may have occurred as a result of the EUA.
This thesis found that there were three main indicators that the EUA supported
innovation in the ventilator industry. The first indicator is that there was new entrance to the
medical device industry. New entrance to the industry was seen not only in companies that
obtained device authorization, but also in partnerships. New entrance and partnerships
accelerated innovative measures by applying a diverse and unique set of skills and knowledge to
the medical device industry. The second indicator is the shift in the types of ventilators seeking
approval. This shift indicates that innovation was stimulated within certain product codes that
may not have been explored before. The last indicator is that there were different forms of
innovation that took place. Innovative approaches were taken regarding the supply chain,
manufacturing, components, and technology. The drive for innovation in these different areas
came from constraints created by a global pandemic.
Because I could not access the EUA applications, I was not able to determine why EUA
approval was needed, especially for pre-existing medical devices. If certain supply,
manufacturing, and design changes are made to a device that would impact its original approved
safety and efficacy, then under usual circumstances a new 510(k) must be submitted. The data
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collected for this thesis cannot tell us, however, if a firm obtained EUA authorization for changes
to a device that would typically require a new 510(k) submission. Nor does it indicate if they did
not pursue the changes prior to the EUA due to the burden of the 510(k) process.
In conclusion, times of emergency often come with a burst of innovation and an
opportunity to bypass traditional paths in the FDA regulatory process. This innovation occurred
when people from all over the world were willing to help fight the COVID-19 battle. There is no
doubt that COVID-19 impacted the amount of innovation that occurred, but this study shows that
there is plenty of room for innovation in the medical device industry to grow. The reduction of
barriers from the EUA resulted in an increase in product improvements and product
development. While my research saw that innovation did occur, only time will tell if these
innovations have a lasting impact on the medical device industry. This leaves opportunities for
future research that will be explained in more detail below.

Limitations
Like any research paper, there were limitations present to this research. The largest
limitation to this study is the use of publicly available data and analysis of public statements. The
data available from the FDA for EUA authorizations was minimal and I could not analyze EUA
submissions or see submissions that were denied or in progress. If this information is available at
some point in the future, an additional analysis could be completed. Due to the limited FDA
information, the methods consisted of analyzing public statements and information on
company’s web pages. When analyzing public statements, there is a risk that the statement may
be inaccurate or misinterpreted. In addition, public statements are often carefully crafted by the
firm to highlight specific information, not to reveal all information. As a result, there is likely
important information missing from these public statements. However, given that I was
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interested in understanding what was novel about a new product, and this is the type of
information that is often used in marketing or in public statements, it is likely that these
statements did reflect to some degree the nature of the innovation in each product. In addition,
the news media was interested in highlighting this innovation and thus solicited information in
this area.
The timeline for thesis completion did not allow for product designs to be investigated in
more detail. Completing further analysis, such as a product decomposition, would provide more
technical answers and explanations to innovation that occurred due to the EUA.
Another limitation is only looking at EUA ventilators. The EUA for medical devices was
also enacted for diagnostic and non-diagnostic devices such as blood purification devices,
diagnostic tests, personal protective equipment, as well as ventilator tubing and accessories.
Additionally, there were likely other ventilator responses outside of the EUA which were not
analyzed. A complete analysis of innovative medical device responses for COVID-19 would
increase this research paper’s external validity.

Implications for Research
While completing this thesis, multiple questions arose that would be interesting to look
into for further research. First, as just discussed, additional details and information could be
researched to validate this thesis’s findings. This includes requesting additional information on
EUA submissions from the FDA and conducting an in-depth analysis of the product design and
components of each EUA device.
Next, there are multiple avenues for future work that can build on the information from
this thesis while investigating different research questions. One of these would-be conducting
interviews with professionals in the health industry, from medical device companies to hospitals.
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This would provide an insider’s perspective on the innovation during this time and would
validate some questions such as COVID-19 and the EUA being the source of this innovation.
Another study that can be done is to do a detailed analysis on if any devices got full FDA
approval, which ones, and if they play a prevalent role in the ventilator market. This study would
not be able to be done until some time after the EUA is revoked and COVID-19 is under control
to ensure the results do not just represent lingering effects from COVID-19.
Building off the literature review, some papers mentioned a negative perception of
working with the FDA. It would be interesting to investigate interactions between companies and
the FDA before and during the EUA process and conduct a sentiment analysis on communication
before, during, and after the EUA. This may provide valuable information regarding how firms’
perceptions of their interactions with the FDA impacts innovations as well.

Implications for Policy and Policy Recommendations
This section will discuss policy implications and provide policy recommendations to
attempt to increase innovation in the medical device industry outside of times of emergency.
EUA
The goal of the EUA is to “promote the development and availability of specific medical
devices and products during national emergencies” (FDA EUA, 2017). The EUA is not a process
that was created specifically for COVID-19. It has been used to manage other viral diseases,
including but not limited to H7N9 in 2013, 2014 Ebola, and the Zika virus. The EUA during
COVID-19 was enacted in response to the need for various medical solutions from diagnostic to
nondiagnostic devices, including ventilators.
The EUA appears to have been successful in its goal of promoting the development and
availability of ventilators. 77 devices were authorized and some of them have led to the
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production of thousands of devices, including those by Ventec and GM (VenTec Life Systems,
2020). The EUA supported creative measures and innovative thinking that sometimes went
beyond what was needed to meet immediate market demand. We also saw that partnerships and
collaborations established in response to the EUA catalyzed the development of innovative
solutions. Based on the performance of the EUA, I would recommend that FDA continue
utilizing the EUA in times of emergency.
Promote Collaboration
In addition to the EUA, the FDA should promote partnerships for small firms and nontraditional medical device companies. In the analysis, we saw that partnerships enabled the
creation and production of authorized devices. If the FDA can foster partnerships, that could
create a more consistent flow of innovation in the medical device industry. This could be done
by establishing a program that facilitates partnerships between companies working towards a
shared goal. Partnerships between universities, small firms, and established medical device
companies as well as medical device companies with other industries will likely stimulate
innovation.
Proactively Responding to Pandemic Plans
Prior to the pandemic, the White House Homeland Security Council outlined the National
Strategy for Pandemic Influenza, Implementation Plan in 2006. This document is meant to be a
live document to be refined as future pandemics occur (Homeland Security Council, 2006).
There have been a few public health crises since 2006, but the document has not been updated.
This document identifies some medical resources that are scarce during a pandemic such as,
hospital and ICU beds, ventilators, and other medical services. Medical staff experience high
amounts of strain during pandemics, resulting in qualified clinicians performing unfamiliar
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functions such as working in a different unit than their specialized training. This requires
ventilators and medical equipment created in a pandemic to use intuitive, innovative solutions so
the device can be used by someone not specially trained to use it.
Additionally, the Department of Health and Human Services (HHS) identified a
ventilator shortage in 2006 and determined that an additional 70,000 would be needed in the case
of a moderate pandemic. The limited national stockpile of ventilators consisted of large,
expensive, difficult to use machines. A partnership was established to develop optimized devices
that cost less than $3,000, ready for mass production by 2010 (Kulish, Kliff, & Silver-Greenberg,
2020). By 2014, the company asked to get out of the government deal, and in the end, no
ventilators were produced for the national stockpile. The fact that 77 devices could be modified
or created by companies in various industries over five months, compared to a four turned 8-year
project that did not result in anything, shows there is a lack of incentives to develop new and
innovative products needed for emergency situations in the medical device industry under
normal conditions.
It is apparent that the government is aware of the impracticality of current full-service
ventilators for both function and quantity during a pandemic. There are multiple regulatory plans
in place to try to manage this issue, but all these strategies call to fix the problem after it occurs.
As soon as a gap in the medical device industry is recognized, such as the need for affordable,
user-friendly ventilators that can be easily mass-produced, this knowledge should be
incorporated into the industry as soon as possible. Suppose the government can foster and help
develop these ideas earlier to avoid stagnancy in innovation in the medical device industry? In
that case, companies have the incentive to implement these innovative solutions at any point
rather than wait for a time when regulatory barriers are reduced such as through the EUA.
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Open-Source Design
One way the government could encourage medical device companies to fill known gaps
in the industry is to establish a government-run database of open-source designs. When a gap is
realized in the medical device industry, action can be taken to incentivize companies to produce
an open-source design. This approach would be less time-intensive for companies compared to
designing and fulfilling an order for thousands of devices. The FDA would best manage the
database as they can work with a company to develop a suitable device that meets all the
requirements. This recommendation could be incentivized by implementing a tax relief or other
type of financial incentive. Companies may be hesitant to create open-source designs as
profitability generally revolves around intellectual property rights. A financial incentive would
provide some sort of return on investments to the company. Additionally, if the open-source
designs are kept private until an emergency like COVID-19 occurs, companies may be more
willing to contribute to this database.
Incentivize Frugal and Accessible Innovation
The last recommendation I have is to incentivize the creation of accessible medical
devices. This can be approached from multiple angles. The first one is incorporating increased
usability into medical device designs and the second is designing for increased accessibility.
Ventilators are only one example of devices that are very expensive and require highly trained
professionals to use them. Underdeveloped communities and countries have minimal access to
many medical devices and companies have little incentive to fill this need. From the COVID-19
EUA, we saw innovative frugal solutions that were easier to use, cost less, and could be used
various locations making them a good option for underdeveloped communities. Incentivizing
companies to create more accessible devices would encourage innovation in various medical
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device categories. This could be done by expanding commercialization assistance programs
(CAP). The National Institute of Health (NIH) implemented a CAP program in 2014 to help
small businesses develop and commercialize their devices. They have been able to help over
1,000 companies since then (NIH CAP, 2020). The NIH could create another CAP program or
build on the current one to involve specialized goals, such as creating accessible devices. Their
experience with this program and recognition of innovative solutions created by small businesses
would provide companies with an excellent opportunity to focus on the need for accessible and
affordable medical devices.
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Appendix
Appendix 1: EUA Products
Company
Beijing Aeonmed Co., Ltd
Shenzhen Mindray Biomedical
Electronics
Vyaire Medical, Inc.

Date
Authorized
3/25/2020

VG70 ventilator

3/28/2020

Mindray SV300/SV600/SV800 ventilators

3/28/2020

Product Name

RESMED

3/30/2020

RESMED

3/30/2020

Amsino

3/31/2020

Inovytec

3/31/2020

RESMED

3/31/2020

RESMED
RESMED
Philips Respironics
BMC Medical Co., LTD
BMC Medical Co., LTD
Dragerwerk AG & CO. KGaA
Dragerwerk AG & CO. KGaA
GE Healthcare
Covidien LLC
CoLabs
MEKICS Co,. Ltd
VenTec Life Systems
Dragerwerk AG & CO. KGaA
Philips Respironics
AMBULANC TECH. CO.,LTD
Incoba LLC
SecondBreath LLC
University of Minnesota Medical
School and Boston Scientific
Corporation
Umbulizer
Hillrom
Spiro Devices LLC
PVA
RESMED
3B Medical Inc
Resvent

3/31/2020
3/31/2020
04/01/2020
04/02/2020
04/02/2020
04/02/2020
04/03/2020
04/03/2020
04/05/2020
04/06/2020
04/06/2020
04/07/2020
04/07/2020
04/08/2020
04/08/2020
04/08/2020
4/13/2020

LTV2 model 2200 and LTV model 2150
Lumis 150 VPAP ST (Amended
April 17, 2020)
Stellar 150
YUWELLÂ® YH-730 Bi-level PAP and YH830 Bi-level PAP
Ventway Sparrow
AirCurve
S T (Amended
April 17, 2020)
Flexo Bi-Level ST
GA ST
VX850 Ventilator
Y-30T
Luna GPAP 25A- LG3700
Evita V800 and Evita V600
Babylog VN800 and VN600
pNeuton Model A-E Ventilator
Puritan Bennett 560 Ventilator System
COVID Ventor
MTV1000 ventilator
V+Pro Emergency Ventilator
Atlan A350 and Atlan A350 XL
E30 ventilator
Models 6000S, T5, T7
Apogee
Pneumatic Resuscitator device

4/14/2020

Coventor Adult Manual Resuscitator Compressor

4/14/2020
4/16/2020
4/17/2020
4/17/2020
4/17/2020
4/20/2020
4/20/2020

Virgin Orbit

4/22/2020

Amsino
AutoMedX Inc.

4/23/2020
4/24/2020

UMV-001 EUA
MetaNeb 4
Spiro Wave (Amended June 8, 2020)
PREVENT
AirCurve 10 ST-A
Luna G3 B30VT
iBreeze PAP
Virgin Orbit Resuscitator (Amended April 23,
2020)
YUWELL YH-725 BiPAP
SAVe II Series Ventilator
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Company
SLS Medical Technology Corp.
Ltd.
Zhejiang LifeMed Technology
Co., Ltd.
Resvent Medical Technology
CO., Ltd's

Shenzhen Yamind Medical Tech

NASA Jet Propulsion
Laboratory
Venti-Now

Date
Authorized

Product Name

4/24/2020

CP101/CP101S Series

4/24/2020

LA Series Ventilators LA20C, LA20A, LA20B,
LA20B, LA25B, LA25B

4/27/2020

iBreeze 30STA device

4/28/2020

CPAP Devices: DM28-20C-G; Auto CPAP
Devices: DM28-20A-W, DM28-20A-WP;
BiPAP Devices: DM28-20S-G, DM28-20SA-G,
DM28-20ST-G, DM28-25S-B, DM28- 25SABP, DM28-25ST-BP, DM28-30ST-B, DM2830ST-BP, DM28-30STA-BP

4/30/2020

VITAL ventilator

4/30/2020

Wilcox Industries Corp

05/01/2020

Wilcox Industries Corp
Elemaster S.p.S. Technologie
Elettroniche
ZIBO ZHONGXUN MEDICAL
EQUIPMENT CO. LTD
JIUXIN MEDICAL
BMC Medical Co., LTD

05/01/2020

Venti-Now Resuscitator Model JM-P2020A
Wilcox PATRIOT SAVR (Amended July 21,
2020)
Wilcox PATRIOT SAVR

05/01/2020

Mechanical Ventilator Milano (MVM)

05/02/2020

ZXH-550

05/02/2020
05/02/2020

Vayu Global Health Innovations

05/05/2020

JIXI H-100
Luna G3 BPAP S/T- LG3800-G3 B30VT
Vayu bubble Continuous Positive Airway
Pressure Circuit ("Vayu bCPAP')

Hunan Beyond Medical
Technology Co., Ltd
Hunan Beyond Medical
Technology Co., Ltd
Guangzhou Hypnus Healthcare
Co., Ltd.
AutoMedX Inc.
Taiyuan Shanghai Medical
Somnetics International, Inc.
Lanick Med Systems LLC
CMI Health

05/06/2020

BEYOND B30P BiPAP

05/06/2020

BEYOND C20A CPAP

05/06/2020

Hypnus ST730

5/7/2020
05/08/2020
05/08/2020
05/07/2020
5/15/2020

SysMed (China) Co., Ltd

5/18/2020

SysMed (China) Co., Ltd

5/20/2020

Origin Medical Devices Inc.
Guangzhou Hypnus Healthcare
Co., Ltd.
Fitbit

5/22/2020

SAVe II+ (M50016, M50017)
Fabius Plus / Fabius Plus XL
Transcend 3 BiPAP
Lyra x1 and Lyra x2 Ventilators
Beijing Aeonmed Shangrila510S
VM series- DPAP20 Plus, DPAP25 Plus,
DPAP25 Pro, DPAP30 Pro
Resware BI 20 S, Resware BI Auto S, Resware
BI 25 S/T, Resware BI 30 S/T, ZiZ Auto, Aurora
Bi-Level S, Aurora Bi-Level S/T, Aurora BiLevel Auto S
Panther 5 Model P5DLVENT

5/22/2020

BA825W, BA825, ST830W and ST830

06/01/2020

Fitbit Flow
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Company
NASA Jet Propulsion
Laboratory
BioMedInnovations, LLC
Nanotronics Imaging, Inc
Enexor BioEnergy, LLC
NeoNatal Rescue, LLC
World Ventilator Foundation
(WVF)
Air Boost
Sagico USA, LLC
Stewart & Stevenson Healthcare
Technologies, LLC
LifeMech, Inc.
Nanotronics Imaging, Inc
VORTRAN Medical Technology
1, INC

Date
Authorized

Product Name

4/30/2020

VITAL Compressor

06/08/2020
06/09/2020
6/10/2020
6/17/2020

SuppleVent
nHale BiPAP device
X-VENT Emergency Ventilator
AdultLife Pro Ventilator

6/19/2020

WorldVent Ventilator

6/24/2020
6/26/2020

AustinP51
V2O SAGICO SYSTEM

6/26/2020

Apollo ABVM

7/31/2020
8/4/2020

LifeMech A-VS
nHale BiPAP device

8/4/2020

VORTRAN GO2VENT with PEEP Valve

Hillrom

8/7/2020

Breas Medical Inc
MICo Medical s.r.o.

8/18/2020
8/21/2020

Life 2000 Ventilation System Product No. BTV5
Z2 Bilevel
MICo Medical CoroVent

Appendix 2: Products with No Data Found
Company
RESMED
Zhejiang LifeMed Technology Co., Ltd.
ZIBO ZHONGXUN MEDICAL EQUIPMENT
CO. LTD
Hunan Beyond Medical Technology Co., Ltd
Hunan Beyond Medical Technology Co., Ltd
Taiyuan Shanghai Medical
BMC Medical
Resmed
Incoba
SysMed (China)

Product
GA ST
LA Series Ventilators LA20C, LA20A, LA20B,
LA20B, LA25B, LA25B
ZXH-550
BEYOND B30P BiPAP
BEYOND C20A CPAP
Fabius Plus / Fabius Plus XL
Luna G3 BPAP S/T- LG3800-G3 B30VT
Flexo Bi-level ST
Apogee
Resware and Aurora Series

Appendix 3: Repeat Devices
Company
Wilcox Industries
AutoMedX Inc.
Nanotronics Imaging
NASA
Resvent Medical Technology

Product
Patriot SAVr
SAVe II Series Ventilator
nHale BiPAP
Vital
iBreeze 30STA
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Appendix 4: Nexis Uni, Company Web Pages, and Google Sources
Company
Beijing Aeonmed Co.,
Ltd

•
•

Shenzhen Mindray
Biomedical
Electronics
Vyaire Medical, Inc.

•
•
•
•

RESMED

•
•

Inovytec

•
•

•

Philips Respironics

•
•
•
•

Sources
Zhang Dan and Yin Yeping. (August 4, 2020 Tuesday). Ventilators still in demand amid global fight
against COVID-19. Global Times (China).
GT staff reporters. (March 24, 2020 Tuesday). Chinese ventilator makers receive orders from US as
pandemic worsens. Global Times (China).
James Pasley. (April 24, 2020 Friday). Singapore's richest man is getting $1 billion richer each month
from selling ventilators. Newstex Blogs The Business Insider.
(April 16, 2020 Thursday). Vyaire Announces HHS Contract to Produce 22,000 Ventilators; Vyaire is one
of seven companies awarded contracts to ramp up ventilator production. PR Newswire.
(April 16, 2020 Thursday). Vyaire Announces HHS Contract to Produce 22,000 Ventilators. Contify Life
Science News.
Vyaire CEO Speaks with McKinsey about Company's COVID-19 Response. (n.d.). Retrieved December
20, 2020, from https://www.vyaire.com/covid-19-news/vyaire-ceo-speaks-mckinsey-about-companyscovid-19-response
(April 30, 2020 Thursday). Q3 2020 Resmed Inc Earnings Call - Final. FD (Fair Disclosure) Wire.
Coronavirus Response. (2020, June 16). Retrieved December 20, 2020, from https://www.resmed.com/enus/covid-19/
(April 21, 2020 Tuesday). Israel fast-tracks ventilator innovations for Covid-19 care. Pharma &
Healthcare Monitor Worldwide.
Rubinstein, C. (2020, May 20). From Missiles To Deadly Viruses: Iron Dome Architects Develop
Innovative Defenses Against COVID-19. Retrieved December 20, 2020, from
https://www.forbes.com/sites/carrierubinstein/2020/05/20/from-missiles-to-deadly-viruses-iron-domearchitects-develop-innovative-defenses-against-covid-19/?sh=522c38455542
Etsion, U. (2020, March 22). Portable Medical Device Developer Inovytec to Provide Israeli Defense
Ministry with 1,000 Respiratory Machines. Retrieved December 20, 2020, from
https://www.calcalistech.com/ctech/articles/0,7340,L-3802855,00.html
VENTWAY SPARROW. (n.d.). Retrieved December 20, 2020, from https://www.inovytec.com/ventway/
First in Critical Care Response. (n.d.). Retrieved December 20, 2020, from https://www.inovytec.com/
VX850 Critical care ventilator. (n.d.). Retrieved December 20, 2020, from
https://www.usa.philips.com/healthcare/product/HC850013/vx850-critical-care-ventilator/overview
COVID-19 response & healthcare solutions: Philips Healthcare. (n.d.). Retrieved December 20, 2020,
from https://www.usa.philips.com/healthcare/medical-specialties/covid-19
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Company
BMC Medical Co.,
LTD
Dragerwerk AG &
CO. KGaA

•
•
•
•
•

•

GE Healthcare

•
•

•
Covidien LLC

•
•

CoLabs

•

MEKICS Co,. Ltd

•
•
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